Stephen V Liu: Rapid communication on management of stage III NSCLC by ASCO
Stephen V Liu shared on X:
“Latest ASCO rapid communication on management of stage III NSCLC. For patients with unresectable stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R, consolidation osimertinib after chemoradiation given strong recommendation, per LAURA.
‘Management of Stage III Non–Small Cell Lung Cancer: ASCO Rapid Recommendation Update‘ | Journal of Clinical Oncology
Authors: Megan E. Daly, Navneet Singh, and Nofisat Ismaila.”
Source: Stephen V Liu/X
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.
His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023